

Rufinamide

Catalog No: tcsc1455

Available Sizes

Size: 10mg

Size: 100mg

Specifications

CAS No:

106308-44-5

Formula:

 $\mathrm{C_{10}H_8F_2N_4O}$

Pathway:

Others

Target:

Others

Purity / Grade:

>98%

Solubility: 10 mM in DMSO

Alternative Names:

CGP 33101;E 2080;RUF 331

Observed Molecular Weight:

238.19

Product Description

Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).

Copyright 2021 Taiclone Biotech Corp.




IC50 Value:

Target:

in vitro:

in vivo: Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean \pm SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline) in mice [1]. Oral rufinamide suppressed pentylenetetrazol-induced seizures in mice (ED(50) 45.8 mg/kg) but not rats, and was active against MES-induced tonic seizures in mice (ED(50) 23.9 mg/kg) and rats (ED(50) 6.1 mg/kg) [2]. Intraperitoneal rufinamide suppressed pentylenetetrazol-, bicuculline-, and picrotoxin-induced clonus in mice (ED(50) 54.0, 50.5, and 76.3 mg/kg, respectively).

Clinical trial: Exploratory Study to Evaluate the Effect of SYN-111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD). Phase 2



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.